CD276 and adenocarcinoma: Although we anticipated that DNA-double strand break repair defects and levels of B7H3 expression would drive B7H3-PBD-ADC responses, we observed high efficacy in (a) select B7H3-low expressing models with no apparent mutations in DNA repair pathway genes, and (b) no response in a group of B7H3+ adenocarcinomas.